首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1136937

肾芽肿治疗药市场:各类型，各药物类型，各流通管道，各地区- 规模，占有率，展望，机会分析，2022年～2030年

Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月29日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格

简介目录

市场动态

各种组织和研究人员为开发肾母细胞瘤治疗方法而增加的研发活动预计将在预测期内推动市场增长。

本调查的主要特征

本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球肾芽肿治疗药市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球肾芽肿治疗药市场的主要参与者之企业简介。
藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
全球肾芽肿治疗药市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以透过全球肾芽肿治疗药市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor. The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy. Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.

Market Dynamics

Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S.

Key features of the study:

This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nephroblastoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market

Detailed Segmentation:

Global Nephroblastoma Treatment Market, By Type:
- Favorable histology
- Anaplastic histology
Global Nephroblastoma Treatment Market, By Drug Type:
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
Global Nephroblastoma Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Nephroblastoma Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Type
- Favorable histology
- Anaplastic histology
  - By Drug Type
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
  - By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Merck & Co., Inc.
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Recordati Rare Diseases
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Actiza Pharmaceutical Private Limited
- Teva Pharmaceutical Industries Ltd.
- Alvogen
- Accord Healthcare Ireland Ltd.
- Baxter
- Amneal Pharmaceuticals LLC.
- Cadila Pharmaceuticals Ltd.
- Company Highlights
- Xediton Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
PEST Analysis
Epidemiology
Product Launch/Approvals

4. Global Nephroblastoma Treatment Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Demand and Supply Analysis

5. Global Nephroblastoma Treatment Market, By Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Favorable histology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Anaplastic histology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Nephroblastoma Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Dactinomycin (Cosmegen)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Doxorubicin (Adriamycin)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Vincristine (Vincasar PFS, Oncovin)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Cyclophosphamide (Cytoxan, Neosar)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Etoposide (Toposar, VePesid)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Irinotecan (Camptosar)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Nephroblastoma Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Nephroblastoma Treatment Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Recordati Rare Diseases
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Actiza Pharmaceutical Private Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alvogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Accord Healthcare Ireland Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amneal Pharmaceuticals LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cadila Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Xediton Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

10. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

肾芽肿治疗药市场:各类型，各药物类型，各流通管道，各地区- 规模，占有率，展望，机会分析，2022年～2030年

Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

市场动态

本调查的主要特征

目录

第1章调查目的与前提条件

第2章市场展望

第3章市场动态，法规，及趋势的分析

第4章肾芽肿治疗药的世界治疗市场:COVID-19影响度分析

第5章肾芽肿治疗药的全球市场:各类型，2017年～2030年

第6章肾芽肿治疗药的全球市场:各药物类型，2017年～2030年

第7章肾芽肿治疗药的全球市场(各流通管道):2017年～2030年

第8章肾芽肿治疗药的全球市场:各地区，2017年～2030年

第9章竞争情形

第10章章节

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Nephroblastoma Treatment Market- COVID-19 Impact Analysis

5. Global Nephroblastoma Treatment Market, By Type, 2017 - 2030, (US$ Million)

6. Global Nephroblastoma Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

7. Global Nephroblastoma Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

8. Global Nephroblastoma Treatment Market, By Region, 2017 - 2030, (US$ Million)

9. Competitive Landscape

10. Section

肾芽肿治疗药市场:各类型，各药物类型，各流通管道，各地区- 规模，占有率，展望，机会分析，2022年～2030年

Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

市场动态

本调查的主要特征

目录

第1章 调查目的与前提条件

第2章 市场展望

第3章 市场动态，法规，及趋势的分析

第4章 肾芽肿治疗药的世界治疗市场:COVID-19影响度分析

第5章 肾芽肿治疗药的全球市场:各类型，2017年～2030年

第6章 肾芽肿治疗药的全球市场:各药物类型，2017年～2030年

第7章 肾芽肿治疗药的全球市场(各流通管道):2017年～2030年

第8章 肾芽肿治疗药的全球市场:各地区，2017年～2030年

第9章 竞争情形

第10章 章节

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Nephroblastoma Treatment Market- COVID-19 Impact Analysis

5. Global Nephroblastoma Treatment Market, By Type, 2017 - 2030, (US$ Million)

6. Global Nephroblastoma Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

7. Global Nephroblastoma Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

8. Global Nephroblastoma Treatment Market, By Region, 2017 - 2030, (US$ Million)

9. Competitive Landscape

10. Section

第1章调查目的与前提条件

第2章市场展望

第3章市场动态，法规，及趋势的分析

第4章肾芽肿治疗药的世界治疗市场:COVID-19影响度分析

第5章肾芽肿治疗药的全球市场:各类型，2017年～2030年

第6章肾芽肿治疗药的全球市场:各药物类型，2017年～2030年

第7章肾芽肿治疗药的全球市场(各流通管道):2017年～2030年

第8章肾芽肿治疗药的全球市场:各地区，2017年～2030年

第9章竞争情形

第10章章节